Mad Money w/ Jim Cramer Mad Money w/ Jim Cramer 1/21/26
Jan 22, 2026
Joe Wolk, Chief Financial Officer of Johnson & Johnson, shares insights into the company’s recent earnings and optimistic guidance for the future. He discusses impressive growth in pharmaceuticals and MedTech, as well as new vision care technologies. Wolk highlights J&J’s strategic acquisitions, particularly in cardiovascular sectors, and the promising prospects of Kapilita in neuroscience. They also touch on how current U.S. policies are supporting life sciences investments, along with J&J's robust defense against litigation.
AI Snips
Chapters
Transcript
Episode notes
Acquisitions Reinforce Key Growth Platforms
- Wolk describes recent acquisitions that materially strengthened J&J's cardiovascular and neuroscience franchises.
- He projects the newly acquired neuroscience asset could become a multi-billion dollar product.
Align Capital Deployment With Policy Tailwinds
- Engage with policymakers and align investment plans to supportive tax and industrial policy.
- Joe Wolk credits U.S. tax and onshoring policies for enabling large domestic investment plans.
Strong Multiple Myeloma Data Boosts Durable Franchise
- J&J reports strong multiple myeloma data combining Darzalex and Tecvayli with high progression-free survival.
- Wolk emphasizes these are durable products not facing imminent loss of exclusivity.